BioAge Labs, Inc. (BIOA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BIOA SEC filings page.
BioAge Labs, Inc. (BIOA) reported $10.4M in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
BioAge is still a development-stage business: research spending far exceeds revenue, while financing—not operations supports cash needs.
In FY2025, the net loss was$80.6M and operating cash flow was-$81.6M , while free cash flow was-$82.3M ; accounting losses are therefore closely translating into cash use rather than reflecting mainly non-cash charges. Investing consumed$95.2M while financing supplied only$11.5M , so reported cash uses exceeded new financing during the year.
Research intensity defines the current economics: R&D reached
The balance sheet shifted sharply from FY2023: total liabilities fell from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of BioAge Labs, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
BioAge Labs, Inc. held $285.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $81.6M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and BioAge Labs, Inc. scores 65/100 among other emerging companies.
BioAge Labs, Inc. had 44M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and BioAge Labs, Inc. scores 3/100 among other emerging companies.
BioAge Labs, Inc. spent $74.0M on research and development in fiscal year 2025, which was 72.7% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and BioAge Labs, Inc. scores 92/100 among other emerging companies.
Not available for BioAge Labs, Inc., and counted as zero in the overall score.
BioAge Labs, Inc.'s operations used $81.6M of cash in fiscal year 2025, against $51.5M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and BioAge Labs, Inc. scores 17/100 among other emerging companies.
BioAge Labs, Inc.'s cash, cash equivalents and investments came to $285.1M at the end of fiscal year 2025, against $22.8M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and BioAge Labs, Inc. scores 97/100 among other emerging companies.
BioAge Labs, Inc. scores 5.21, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($255.6M) relative to total liabilities ($22.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
BioAge Labs, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
BioAge Labs, Inc. reported a net loss of $80.6M while operations used $81.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
BioAge Labs, Inc. reported an operating loss of $92.8M against $697K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BioAge Labs, Inc. generated $2.5M in revenue in Q2 2026. This represents an increase of 1.6% from the same quarter a year earlier. Against the prior quarter it is down 11.6%.
BioAge Labs, Inc. reported -$26.1M in net income in Q2 2026. This represents a decrease of 21.0% from the same quarter a year earlier. Against the prior quarter it is down 17.3%.
BioAge Labs, Inc. earned -$0.58 per diluted share (EPS) in Q2 2026. This represents an increase of 3.3% from the same quarter a year earlier. Against the prior quarter it is down 11.5%.
Not reported for Q2 2026.
Cash & Balance Sheet
BioAge Labs, Inc. recorded an outflow of $19.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 2.7% from the same quarter a year earlier. Against the prior quarter it is up 18.6%.
BioAge Labs, Inc. held $74.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
BioAge Labs, Inc.'s ROE was -7.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.1 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
BioAge Labs, Inc. invested $24.4M in research and development in Q2 2026. This represents an increase of 22.8% from the same quarter a year earlier. Against the prior quarter it is up 19.4%.
BioAge Labs, Inc. invested $328K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 106.3% from the same quarter a year earlier. Against the prior quarter it is up 1161.5%.
Not reported for Q2 2026.
BIOA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M+1.6% | $2.8M+91.0% | $3.1M | $2.1M | $2.4M | $1.5M | N/A | $0 |
| R&D Expenses | $24.4M+22.8% | $20.4M+83.7% | $24.5M | $18.5M-7.5% | $19.8M+89.5% | $11.1M+19.2% | N/A | $20.0M+206.5% |
| SG&A Expenses | $7.4M+1.1% | $7.7M+14.0% | $7.0M | $6.7M+41.2% | $7.3M+53.0% | $6.8M+94.4% | N/A | $4.7M+41.0% |
| Operating Income | -$29.3M-18.4% | -$25.4M-54.3% | -$28.4M | -$23.1M+6.5% | -$24.8M-62.2% | -$16.4M-28.4% | N/A | -$24.8M-150.3% |
| Interest Expense | $1K-99.5% | $39K-84.7% | $92K | $149K-61.6% | $201K-54.6% | $255K-79.0% | N/A | $388K-83.9% |
| Net Income | -$26.1M-21.0% | -$22.3M-72.1% | -$25.9M | -$20.2M+13.8% | -$21.6M-58.8% | -$12.9M+0.5% | N/A | -$23.4M-60.0% |
| EPS (Basic) | -$0.58+3.3% | -$0.52-44.4% | -$0.72-104.8% | -$0.56+91.6% | -$0.60+92.4% | -$0.36+95.4% | $15.13+220.8% | -$6.70+23.3% |
| EPS (Diluted) | -$0.58+3.3% | -$0.52-44.4% | -$0.72-104.8% | -$0.56 | -$0.60 | -$0.36 | $15.13 | -$6.70 |
| Diluted Shares (Avg) | 45M+25.1% | 42M+18.5% | N/A | 36M | 36M | 36M | N/A | 3M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA, Income Tax.
BIOA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $396.9M+23.2% | $397.7M+15.7% | $294.9M-17.7% | $305.1M-9.6% | $322.1M | $343.8M | $358.2M+1281.9% | $337.4M |
| Current Assets | $330.3M+9.5% | $391.9M+20.6% | $286.8M-19.7% | $290.8M-13.6% | $301.7M | $324.8M | $357.1M+1311.1% | $336.5M |
| Cash & Equivalents | $74.0M-66.4% | $241.8M-6.1% | $188.9M-46.7% | $215.6M-35.5% | $220.3M | $257.5M+48.0% | $354.3M+1537.2% | $334.5M |
| Short-Term Investments | $244.8M+218.0% | $141.4M+124.4% | $92.2M | $70.2M | $77.0M | $63.0M | $0 | $0 |
| Accounts Receivable | $625K+3.6% | $709K+96.4% | $769K | $515K | $603K | $361K | $0 | N/A |
| Long-Term Investments | $62.5M+288.2% | $1.7M+1600.0% | $4.0M+3900.0% | $10.1M+10000.0% | $16.1M | $100K | $100K0.0% | $100K |
| Total Liabilities | $22.0M-19.6% | $18.5M-39.6% | $22.8M-34.9% | $27.6M+16.9% | $27.4M | $30.7M | $35.1M-82.4% | $23.6M |
| Current Liabilities | $19.2M-15.9% | $15.8M-33.3% | $20.1M-27.5% | $24.5M+28.4% | $22.8M | $23.7M | $27.8M-52.3% | $19.1M |
| Non-Current Liabilities | $2.8M-38.2% | $2.7M-61.0% | $2.7M-63.2% | $3.1M-31.2% | $4.5M | $6.9M | $7.3M-94.8% | $4.6M |
| Long-Term Debt | N/A | N/A | $0-100.0% | $0-100.0% | $0 | $1.1M | $2.5M-69.5% | $3.9M |
| Total Equity | $374.9M+27.2% | $379.1M+21.1% | $272.1M-15.8% | $277.5M-11.6% | $294.8M+249.5% | $313.2M+268.8% | $323.1M+286.4% | $313.7M+304.9% |
| Retained Earnings | -$381.8M-32.9% | -$355.7M-33.8% | -$333.4M-31.9% | -$307.5M-32.7% | -$287.3M | -$265.7M | -$252.8M-39.1% | -$231.7M |
Not reported in any period shown, so not listed: Inventory, Goodwill.
BIOA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.3M+3.6% | -$24.0M-38.5% | -$28.3M-449.8% | -$16.0M-7.5% | -$20.0M-26.5% | -$17.4M-10.8% | -$5.1M+39.6% | -$14.9M |
| Depreciation & Amortization | N/A | N/A | N/A | N/A | N/A | N/A | $100K0.0% | N/A |
| Stock-Based Compensation | $4.3M+32.2% | $4.3M+44.3% | N/A | $2.8M+51.0% | $3.2M+107.3% | $2.9M+246.1% | N/A | $1.8M+144.1% |
| Capital Expenditures | $328K+106.3% | $26K-93.9% | $112K+330.8% | $22K-92.8% | $159K+354.3% | $426K | $26K | $305K |
| Free Cash Flow | -$19.6M+2.7% | -$24.1M-35.3% | -$28.4M-449.2% | -$16.1M-5.4% | -$20.1M-27.3% | -$17.8M-13.5% | -$5.2M+39.3% | -$15.2M |
| Investing Cash Flow | -$164.5M-951.8% | -$46.8M+40.1% | -$14.4M-55392.3% | $12.8M+4310.2% | -$15.6M-44588.6% | -$78.0M | -$26K | -$305K |
| Financing Cash Flow | $16.0M+1164.4% | $123.7M+8347.7% | $16.0M-35.7% | -$1.5M-100.8% | -$1.5M+37.2% | -$1.5M-100.9% | $24.9M+2568.0% | $190.7M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BIOA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1196.8% | -915.4% | -923.4% | -1126.6% | -1027.0% | -1133.4% | N/A | N/A |
| Net Margin | -1064.8% | -802.8% | -842.8% | -982.0% | -894.0% | -891.0% | N/A | N/A |
| Return on Equity | -7.0%+0.4pp | -5.9%-1.7pp | -9.5% | -7.3%+0.2pp | -7.3% | -4.1% | N/A | -7.5% |
| Return on Assets | -6.6%+0.1pp | -5.6%-1.8pp | -8.8% | -6.6%+0.3pp | -6.7% | -3.8% | N/A | -6.9% |
| Current Ratio | 17.19+4.0x | 24.76+11.1x | 14.24+1.4x | 11.87-5.8x | 13.21 | 13.68 | 12.86+12.4x | 17.63 |
| Debt-to-Equity | 0.06+0.1x | 0.050.0x | 0.000.0x | 0.000.0x | 0.00 | 0.00 | 0.01 | 0.01 |
| Asset Turnover | 0.010.0x | 0.010.0x | 0.01 | 0.010.0x | 0.01 | 0.00 | N/A | 0.00 |
| FCF Margin | -799.2% | -868.4% | -921.5% | -782.2% | -834.5% | -1226.0% | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BioAge Labs, Inc. BIOA | FY2025 | $9.0M | -$80.6M | N/A | $255.6M | 46/100 |
| Ironwood Pharmaceuticals, Inc. IRWD | FY2025 | $296.2M | $24.0M | 8.1% | $621.3M | 34/100 |
| Journey Medical Corporation DERM | FY2025 | $61.9M | -$11.4M | -18.5% | $166.8M | 20/100 |
| Citius Oncology, Inc. CTOR | FY2025 | N/A | -$24.8M | N/A | $85.9M | — |
| China SXT Pharmaceuticals, Inc. SXTC | FY2026 | $1.1M | -$6.2M | N/A | $135K | 33/100 |
Where BioAge Labs, Inc. Ranks
Frequently Asked Questions
What is BioAge Labs, Inc.'s annual revenue?
BioAge Labs, Inc. (BIOA) reported $9.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is BioAge Labs, Inc. profitable?
No, BioAge Labs, Inc. (BIOA) reported a net income of -$80.6M in fiscal year 2025.
What is BioAge Labs, Inc.'s EBITDA?
BioAge Labs, Inc. (BIOA) had EBITDA of -$92.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does BioAge Labs, Inc. have?
As of fiscal year 2025, BioAge Labs, Inc. (BIOA) had $188.9M in cash and equivalents against $0 in long-term debt.
What is BioAge Labs, Inc.'s return on equity (ROE)?
BioAge Labs, Inc. (BIOA) has a return on equity of -29.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BioAge Labs, Inc.'s free cash flow?
BioAge Labs, Inc. (BIOA) recorded an outflow of $82.3M in free cash flow during fiscal year 2025. This represents a -58.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BioAge Labs, Inc.'s operating cash flow?
BioAge Labs, Inc. (BIOA) recorded an outflow of $81.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are BioAge Labs, Inc.'s total assets?
BioAge Labs, Inc. (BIOA) had $294.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are BioAge Labs, Inc.'s capital expenditures?
BioAge Labs, Inc. (BIOA) invested $719K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does BioAge Labs, Inc. spend on research and development?
BioAge Labs, Inc. (BIOA) invested $74.0M in research and development during fiscal year 2025.
What is BioAge Labs, Inc.'s current ratio?
BioAge Labs, Inc. (BIOA) had a current ratio of 14.24 as of fiscal year 2025, which is generally considered healthy.
What is BioAge Labs, Inc.'s debt-to-equity ratio?
BioAge Labs, Inc. (BIOA) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BioAge Labs, Inc.'s return on assets (ROA)?
BioAge Labs, Inc. (BIOA) had a return on assets of -27.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BioAge Labs, Inc.'s P/E ratio?
BioAge Labs, Inc. (BIOA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $255.6M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BioAge Labs, Inc.'s price-to-sales ratio?
BioAge Labs, Inc. (BIOA) trades at 24.7x sales, its market capitalization divided by revenue of $10.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $255.6M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does BioAge Labs, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, BioAge Labs, Inc. (BIOA) held $285.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $81.6M over that year. Dividing the one by the other, the reported balance equals about 42 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is BioAge Labs, Inc.'s Altman Z-Score?
BioAge Labs, Inc. (BIOA) has an Altman Z-Score of 5.21, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is BioAge Labs, Inc.'s Piotroski F-Score?
BioAge Labs, Inc. (BIOA) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioAge Labs, Inc.'s earnings high quality?
BioAge Labs, Inc. (BIOA) reported a net loss of $80.6M while operations used $81.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BioAge Labs, Inc. cover its interest payments?
BioAge Labs, Inc. (BIOA) reported an operating loss of $92.8M against $697K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is BioAge Labs, Inc.?
BioAge Labs, Inc. (BIOA) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.